Zobrazeno 1 - 10
of 18
pro vyhledávání: '"Rachel Langland"'
Autor:
Fernando Lopez-Rios, Barbara Angulo, Belen Gomez, Debbie Mair, Rebeca Martinez, Esther Conde, Felice Shieh, Jeffrey Vaks, Rachel Langland, H Jeffrey Lawrence, David Gonzalez de Castro
Publikováno v:
PLoS ONE, Vol 8, Iss 1, p e53733 (2013)
The cobas 4800 BRAF V600 Mutation Test is a CE-marked and FDA-approved in vitro diagnostic assay used to select patients with metastatic melanoma for treatment with the selective BRAF inhibitor vemurafenib. We describe the pre-approval validation of
Externí odkaz:
https://doaj.org/article/8b7c7ba839a0413692b4b920d1c8bd92
Autor:
Pooja Vinay, Rachel Langland, Jennifer Govero, Nitin Mahajan, Anna Ballard, Andrew Martens, Liz Schwarzkopf, Tom Leedom, David H. Spencer, Somayeh Pouyanfard, Andrew Espenschied, Alexander S. Hamil, Kenneth M Chrobak, Matthew L. Cooper, Ayman Kabakibi, Michael R. James
Publikováno v:
Blood. 138:2772-2772
Background T-cell Acute Lymphoblastic Leukemia (T-ALL) / Lymphoblastic Lymphoma (LBL) represent a class of devastating hematologic cancers with high rates of relapse and mortality in both children and adults. Development of CAR-T cell therapies for T
Autor:
Luca Santarelli, Eriene A. Youssef, Jorge A. Quiroz, Christian Czech, Paulo Fontoura, Randi J Hagerman, Elizabeth Berry-Kravis, Russell Kinch, Lothar Lindemann, Michael Rabbia, Dennis Deptula, Rachel Langland, Chin Y Wong, Moritz Marcinowski, David R Hessl, Philip Drewitt, Carsten Horn, Amy John
Publikováno v:
Neuropsychopharmacology
Preclinical data suggest that inhibition of the metabotropic glutamate receptor 5 (mGluR5) receptor might hold therapeutic benefits in Fragile X syndrome (FXS). Treatment of Fmr1 knockout mice with mGluR5-negative allosteric modulators (NAMs) has bee
Autor:
Sweta Shah, Kelli DeMartin, Grantland Hillman, Harkanwal Halait, Suzanne Cheng, H. Jeffrey Lawrence, Lin Wu, Rachel Langland, Stephen Soviero
Publikováno v:
Diagnostic Molecular Pathology. 21:1-8
Melanomas frequently harbor BRAFV600 mutations. Vemurafenib (RG7204/PLX4032), a small-molecule inhibitor of mutant BRAF, has shown striking clinical efficacy in BRAFV600 mutant melanoma, creating the need for a well-validated companion diagnostic to
Autor:
Rachel Langland, Jeanne Tie, Gideon Bollag, Jayesh Desai, Matthew Croxford, Ian T. Jones, K. B. Nolop, Oliver M. Sieber, Daniel McKay, Robert N. Jorissen, Michael Christie, Peter Gibbs, Suzanne Kosmider, Lara Lipton, Antony W. Burgess
Publikováno v:
International Journal of Cancer. 128:2075-2084
BRAF(V600E) mutations are found in 10% of colorectal cancers (CRCs). The low frequency of this mutation therefore makes it a challenging target for drug development, unless subsets of patients with higher rates of BRAF(V600E) can be defined. Knowledg
Publikováno v:
Journal of Clinical Oncology. 36:e24153-e24153
e24153Background: Activating mutations in the mitogen-activated protein kinase pathway are among the most common mutations found in cancer cells. Because of the interaction between BRAF and NRAS, t...
Publikováno v:
Developmental Biology. 240:377-386
VegT is an essential maternal regulator of germ layer specification in Xenopus. The localization of VegT mRNA to the vegetal cortex of the oocyte during oogenesis ensures its inheritance by vegetal and not animal cells, and directs the differentiatio
Publikováno v:
Experimental Cell Research. 234:132-138
Cytotoxic necrotizing factor 2 (CNF2) is an exotoxin identified from virulent clinical isolates of Escherichia coli. It has been characterized in adherent cell lines as an inducer of cellular death, hyperploidy (multinucleation), and cytoskeletal reo
Autor:
Debbie Mair, H. Jeffrey Lawrence, Belen Gomez, Fernando Lopez-Rios, Jeffrey Vaks, Rebeca Martinez, Felice Shieh, David Gonzalez de Castro, Rachel Langland, Barbara Angulo, Esther Conde
Publikováno v:
PLoS ONE
PLoS ONE, Vol 8, Iss 1, p e53733 (2013)
PLoS ONE, Vol 8, Iss 1, p e53733 (2013)
Background: The cobas 4800 BRAF V600 Mutation Test is a CE-marked and FDA-approved in vitro diagnostic assay used to select patients with metastatic melanoma for treatment with the selective BRAF inhibitor vemurafenib. We describe the pre-approval va
Autor:
Pam Ochoa, Robert Schilling, Rachel Langland, Steven M. Anderson, Barbara Kovach, H. Jeffrey Lawrence, Harkanwal Halait, Ju Ruey-Jiuan Lee, Kenneth J. Bloom, Cliff Meldrum, Michael C. Dugan, Dino U. Vallera, Josef Rueschoff
Publikováno v:
Archives of pathologylaboratory medicine. 136(11)
Context.—A polymerase chain reaction–based companion diagnostic (cobas 4800 BRAF V600 Mutation Test) was recently approved by the US Food and Drug Administration to select patients with BRAF-mutant metastatic melanoma for treatment with the BRAF